Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
8452876 | Hematology/Oncology and Stem Cell Therapy | 2017 | 17 Pages |
Abstract
Mantle cell lymphoma is a clinically heterogeneous disease occurring within a heterogeneous patient population, highlighting a need for personalized therapy to ensure optimal outcomes. It is therefore critical to understand the benefits and risks associated with both intensive and deintensified approaches. In the following review we provide a therapeutic roadmap to strategically guide treatment for newly diagnosed and relapsed/refractory patients highlighting pivotal and recently published results involving known and novel therapies.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Jose D. Sandoval-Sus, Eduardo M. Sotomayor, Bijal D. Shah,